Progressive Pulmonary Fibrosis: Where Are We Now?
Tuberculosis and Respiratory Diseases · 01.04.2024 · 87 (2) · 123-133
DOI: 10.4046/trd.2023.0119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tuberculosis and Respiratory Diseases, erschienen am 01.04.2024. Verfasst von Hyung Koo Kang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Me…. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, Korea Environment Industry and Technology Institute.
Abstract (Originalsprache)
Interstitial lung diseases (ILDs) are a diverse collection of lung disorders sharing similar features, such as inflammation and fibrosis. The diagnosis and management of ILD require a multidisciplinary approach using clinical, radiological, and pathological evaluation. Progressive pulmonary fibrosis (PPF) is a distinct form of progressive and fibrotic disease, occurring in ILD cases other than in idiopathic pulmonary fibrosis (IPF). It is defined based on clinical symptoms, lung function, and chest imaging, regardless of the underlying condition. The progression to PPF must be monitored through a combination of pulmonary function tests (forced vital capacity [FVC] and diffusing capacity of the lung for carbon monoxide), an assessment of symptoms, and computed tomography scans, with regular follow-up. Although the precise mechanisms of PPF remain unclear, there is evidence of shared pathogenetic mechanisms with IPF, contributing to similar disease behavior and worse prognosis compared to non-PPF ILD. Pharmacological treatment of PPF includes immunomodulatory agents to reduce inflammation and the use of antifibrotics to target progressive fibrosis. Nintedanib, a known antifibrotic agent, was found to be effective in slowing IPF progression and reducing the annual rate of decline in FVC among patients with PPF compared to placebos. Nonpharmacological treatment, including pulmonary rehabilitation, supplemental oxygen therapy, and vaccination, also play important roles in the management of PPF, leading to comprehensive care for patients with ILD. Although there is currently no cure for PPF, there are treatments that can help slow the progression of the disease and improve quality of life.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea.
- Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
- Korea Environment Industry and Technology Institute
- Korea Ministry of the Environment
Zitieren
APA
Kang, H. K., & Song, J. W. (2024). Progressive Pulmonary Fibrosis: Where Are We Now?. Tuberculosis and Respiratory Diseases, 87(2), 123-133. https://doi.org/10.4046/trd.2023.0119
Vancouver
Kang HK, Song JW. Progressive Pulmonary Fibrosis: Where Are We Now?. Tuberculosis and Respiratory Diseases. 2024;87(2):123-133. doi:10.4046/trd.2023.0119
BibTeX
@article{Kang2024,
author = {Kang, Hyung Koo and Song, Jin Woo},
title = {Progressive Pulmonary Fibrosis: Where Are We Now?},
journal = {Tuberculosis and Respiratory Diseases},
year = {2024},
volume = {87},
number = {2},
pages = {123--133},
doi = {10.4046/trd.2023.0119}
}
EUVIMED